Market Research Logo

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2015

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2015’, provides an overview of the Alpha- Antitrypsin Deficiency’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Alpha- Antitrypsin Deficiency and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Alpha- Antitrypsin Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Alpha- Antitrypsin Deficiency pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Alpha- Antitrypsin Deficiency Overview
Therapeutics Development
Pipeline Products for Alpha- Antitrypsin Deficiency - Overview
Pipeline Products for Alpha- Antitrypsin Deficiency - Comparative Analysis
Alpha- Antitrypsin Deficiency - Therapeutics under Development by Companies
Alpha- Antitrypsin Deficiency - Therapeutics under Investigation by Universities/Institutes
Alpha- Antitrypsin Deficiency - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Alpha- Antitrypsin Deficiency - Products under Development by Companies
Alpha- Antitrypsin Deficiency - Products under Investigation by Universities/Institutes
Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Research Corporation
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Grifols, S.A.
iBio, Inc.
Inhibrx
International Stem Cell Corporation
Intrexon Corporation
Isis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
Promethera Biosciences S.A.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Alpha- Antitrypsin Deficiency - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALN-AAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha-1 Antitrypsin With rHuPH20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alpha-1 proteinase inhibitor (human) second generation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARC-AAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT-2009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate A1AT for Alpha 1-Antitrypsin Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha- Antitrypsin Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-AATRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
POL-6014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAAV2-CB-hAAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant A1PI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Alpha-1 Antitrypsin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Alpha-1 Antitrypsin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Alpha-1 Antitrypsin Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha- Antitrypsin Deficiency - Recent Pipeline Updates
Alpha- Antitrypsin Deficiency - Dormant Projects
Alpha- Antitrypsin Deficiency - Discontinued Products
Alpha- Antitrypsin Deficiency - Product Development Milestones
Featured News & Press Releases
Jul 08, 2015: Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand
Jul 02, 2015: Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency
Jun 10, 2015: Arrowhead Receives Orphan Drug Designation for ARC-AAT
May 20, 2015: Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency
May 05, 2015: Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT
Apr 20, 2015: Kamada Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency
Feb 23, 2015: Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency
Jan 07, 2015: Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD
Nov 18, 2014: Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT
Nov 10, 2014: Arrowhead Presents Data on ARC-AAT at AASLD The Liver Meeting 2014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2015
Number of Products under Development for Alpha- Antitrypsin Deficiency - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Applied Genetic Technologies Corporation, H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Arrowhead Research Corporation, H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Carolus Therapeutics, Inc., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Cevec Pharmaceuticals GmbH, H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Grifols, S.A., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by iBio, Inc., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Inhibrx, H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by International Stem Cell Corporation, H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Intrexon Corporation, H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Kamada Ltd., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Polyphor Ltd., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Promethera Biosciences S.A., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by rEVO Biologics, Inc., H2 2015
Alpha- Antitrypsin Deficiency - Pipeline by Sangamo BioSciences, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Alpha- Antitrypsin Deficiency Therapeutics - Recent Pipeline Updates, H2 2015
Alpha- Antitrypsin Deficiency - Dormant Projects, H2 2015
Alpha- Antitrypsin Deficiency - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2015
Number of Products under Development for Alpha- Antitrypsin Deficiency - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report